FDA Places Clinical Hold on Halozyme's (HALO) PEGPH20 Phase 2 Enrollment
Tweet Send to a Friend
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that the United States Food and Drug Administration (FDA) informed the company yesterday that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE